- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Supernus Pharmaceuticals, Inc.(SUPN)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Advisory Performance History (Simulated)
Upturn Advisory & Investor View for SUPN
11/13/2026: SUPN (5-star) is a STRONG-BUY. BUY for 1 day. Simulated Profits (0.00%). Updated daily EoD!
Supernus Pharmaceuticals is a specialty company focused on developing and commercializing branded drugs for epilepsy and ADHD. The firm has a leading position in niche CNS segments, relying on its proficiency in creating differentiated, extended-release formulations. The company's primary growth opportunity centers on the commercial expansion of Qelbree, while its main risks involve pending patent cliffs for legacy epilepsy drugs and ongoing competition from generic manufacturers. The stock may interest growth-oriented investors looking for CNS exposure, though they should be prepared for significant volatility. Investors should monitor Qelbree’s quarterly sales growth and outcomes from legal challenges related to its patent portfolio.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | The company's growth depends on the successful adoption of newer products like Qelbree to offset declining legacy revenues. |
| Momentum investor | Weak fit | Momentum is inconsistent as the stock often reacts sharply to patent news and drug launch data. |
| Value investor | Mixed fit | The stock may appear undervalued on certain metrics, but business quality risks and patent cliffs complicate the valuation thesis. |
| Dividend investor | Weak fit | Supernus does not pay a dividend, making it unsuitable for income-focused portfolios. |
| Low-risk investor | Weak fit | Small-cap pharmaceutical stocks carry inherent regulatory and clinical trial risks that create significant volatility. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | The stock is susceptible to large price swings based on clinical data releases and litigation outcomes. |
| Valuation risk | Medium | Valuation is sensitive to long-term projections of Qelbree revenue and the competitive landscape. |
| Competition risk (generic/branded) | High | Generic competition for legacy products poses a persistent threat to margins and revenue stability. |
| Business quality | Medium | The business relies on a few key products, creating a concentration risk in its revenue stream. |
| Dividend income | Low / none | No dividends are provided, so there is no income component to the total return. |
| Execution risk | Medium / high | Success depends heavily on marketing execution for Qelbree and R&D efficiency. |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 6.17B USD | Price to earnings Ratio - | 1Y Target Price 54.14 |
Price to earnings Ratio - | 1Y Target Price 54.14 | ||
Volume (30-day avg) 3.5M shares | Beta 1.13 | 52 Weeks Range 21.48 - 33.22 | Updated Date 11/14/2026 |
52 Weeks Range 21.48 - 33.22 | Updated Date 11/14/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.76 |
Sector & Industry Intelligence
Sector
Healthcare
Bullish- Sentiment
- Strong Bullish
- Momentum
- Momentum Steady
- BUY participation
- 62.6%
- Active BUY / eligible
- 72 / 115
- 30-Day BUY Count Change
- +35
- Market state
- Strong Bullish
The number of qualifying BUY stocks has remained relatively stable.
Industry
Drug Manufacturers - Specialty & Generic
- BUY participation
- 66.7%
- Active BUY / eligible
- 8 / 12
- 30-Day BUY Count Change
- +3
Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.
Price Behavior

Strong Uptrend
The stock has maintained a strong upward price trend across the last three quarters.

Moderately Choppy
The stock has experienced noticeable price swings while retaining some directional structure.
Analysis of Past Performance
Type Stock | Historic Profit 141.07% | Avg. Invested days 39 | Today’s Advisory Strong Buy |
Upturn Advisory Rating ![]() | Upturn Advisory Performance | Stock Returns Performance |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals 
Financial Health Rating 
Growth Momentum Score 
Ownership 
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue) 
Economic Dimensions
Quantitative Style Profile 
Style Classification
Quality Focused
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| CNS Pharmaceuticals | Sales of branded drugs for epilepsy, migraine, and ADHD, primarily in the US market. | The company generates revenue by selling specialized, patented prescription drugs to patients managing brain-related conditions. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2026-10-29 | When Before Market | Estimate 0.34 | Actual 0.78 |
Profitability
Profit Margin 32.75% | Operating Margin (TTM) 46.94% |
Management Effectiveness
Return on Assets (TTM) 29.34% | Return on Equity (TTM) -4.15% |
Valuation
Trailing PE - | Forward PE 20.16 | Enterprise Value 5.85B | Price to Sales(TTM) 4.49 |
Enterprise Value 5.85B | Price to Sales(TTM) 4.49 | ||
Enterprise Value to Revenue 6.76 | Enterprise Value to EBITDA 96.3 | Shares Outstanding 207.72M | Shares Floating 114.74M |
Shares Outstanding 207.72M | Shares Floating 114.74M | ||
Percent Insiders 2.65 | Percent Institutions 59.73 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.

